Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano J Costa

Showing results (1-10 of 197) with videos related to

Pageof 20
Sort By:
Blood|July 25, 2024
MRD accelerating myeloma drug developmentLuciano J Costa
The Lancet. Haematology|May 4, 2020
Clinical trial materialLuciano J Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Fewer scans, better careLuciano J Costa
British Journal of Haematology|June 27, 2009
Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimenLuciano J Costa
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Insights into the assessment of measurable residual disease (MRD) in patients with multiple myelomaLuciano J Costa
The Lancet. Haematology|March 28, 2022
MGIP, MGUS, and the PROMISE of meaning in small thingsAnita D'Souza, Luciano J Costa
Cancer|September 23, 2020
Age is just a number, the wrong numberSusan Bal, Luciano J Costa
American Journal of Hematology|July 10, 2025
Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?Hira Mian, Luciano J Costa
Blood Cancer Discovery|November 26, 2024
Total (Immuno)Therapy: Version 2.0Susan Bal, Luciano J Costa
The Lancet. Haematology|May 28, 2021
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapySusan Bal, Luciano J Costa
Pageof 20

Showing results (1-10 of 197) with videos related to

Sort By:
Pageof 20
Blood|July 25, 2024
MRD accelerating myeloma drug developmentLuciano J Costa
The Lancet. Haematology|May 4, 2020
Clinical trial materialLuciano J Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Fewer scans, better careLuciano J Costa
British Journal of Haematology|June 27, 2009
Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimenLuciano J Costa
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Insights into the assessment of measurable residual disease (MRD) in patients with multiple myelomaLuciano J Costa
The Lancet. Haematology|March 28, 2022
MGIP, MGUS, and the PROMISE of meaning in small thingsAnita D'Souza, Luciano J Costa
Cancer|September 23, 2020
Age is just a number, the wrong numberSusan Bal, Luciano J Costa
American Journal of Hematology|July 10, 2025
Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?Hira Mian, Luciano J Costa
Blood Cancer Discovery|November 26, 2024
Total (Immuno)Therapy: Version 2.0Susan Bal, Luciano J Costa
The Lancet. Haematology|May 28, 2021
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapySusan Bal, Luciano J Costa
Pageof 20